Qiu-Yan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qiu-Yan Zhang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Guang Liang
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
2 shared publications - Aleksandr Vladimirovich Samorodov
Башкирский государственный медицинский университет
1 shared publication Daona Yang
The Affiliated Cangnan Hospital, Wenzhou Medical University, Cangnan, Zhejiang 325800, China
1 shared publication- Jianchang Qian
Institute of Molecular Toxicology and Pharmacology, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
1 shared publication - Jibo Han
Department of Cardiology The Second Affiliated Hospital of Jiaxing University Jiaxing Zhejiang China
1 shared publication - Joo Young Huh
College of Pharmacy, Chung-Ang University, Seoul, Korea
1 shared publication
Latest Publications
- 12 October 2022
- Published by Elsevier in Phytomedicine
- Vol. 108, 154489
Schisandrin B protects against LPS-induced inflammatory lung injury by targeting MyD88
- 12 October 2022
- Published by Elsevier in Phytomedicine
- Vol. 108, 154489
Schisandrin B protects against LPS-induced inflammatory lung injury by targeting MyD88
- Open Access
- 22 September 2021
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 43 (2) , 354-366
Pharmacological inhibition of MyD88 suppresses inflammation in tubular epithelial cells and prevents diabetic nephropathy in experimental mice
Emerging evidence shows that chronic inflammation mediated by toll-like receptors (TLRs) contributes to diabetic nephropathy. Myeloid differentiation primary-response protein-88 (MyD88) is an essential adapter protein of all TLRs except TLR3 in innate immunity. It is unclear whether MyD88 could be a therapeutic target for diabetic nephropathy. Here, we used a new small-molecule MyD88 inhibitor, LM8, to examine the pharmacological inhibition of MyD88 in protecting kidneys from inflammatory injury in diabetes. We showed that MyD88 was significantly activated in the kidney of STZ-induced type 1 diabetic mice in tubular epithelial cells as well as in high glucose-treated rat tubular epithelial cells NRK-52E. In cultured tubular epithelial cells, we show that LM8 (2.5−10 μM) or MyD88 siRNA attenuated high-concentration glucose-induced inflammatory and fibrogenic responses through inhibition of MyD88-TLR4 interaction and downstream NF-κB activation. Treatment with LM8 (5, 10 mg/kg, i.g.) significantly reduced renal inflammation and fibrosis and preserved renal function in both type 1 and type 2 diabetic mice. These renoprotective effects were associated with reduced MyD88-TLR4 complex formation, suppressed NF-κB signaling, and prevention of inflammatory factor expression. Collectively, our results show that hyperglycemia activates MyD88 signaling cascade to induce renal inflammation, fibrosis, and dysfunction. Pharmacological inhibition of MyD88 may be a therapeutic approach to mitigate diabetic nephropathy and the inhibitor LM8 could be a potential candidate for such therapy.
- 22 September 2021
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 43 (2) , 354-366
Open AccessPharmacological inhibition of MyD88 suppresses inflammation in tubular epithelial cells and prevents diabetic nephropathy in experimental mice
Emerging evidence shows that chronic inflammation mediated by toll-like receptors (TLRs) contributes to diabetic nephropathy. Myeloid differentiation primary-response protein-88 (MyD88) is an essential adapter protein of all TLRs except TLR3 in innate immunity. It is unclear whether MyD88 could be a therapeutic target for diabetic nephropathy. Here, we used a new small-molecule MyD88 inhibitor, LM8, to examine the pharmacological inhibition of MyD88 in protecting kidneys from inflammatory injury in diabetes. We showed that MyD88 was significantly activated in the kidney of STZ-induced type 1 diabetic mice in tubular epithelial cells as well as in high glucose-treated rat tubular epithelial cells NRK-52E. In cultured tubular epithelial cells, we show that LM8 (2.5−10 μM) or MyD88 siRNA attenuated high-concentration glucose-induced inflammatory and fibrogenic responses through inhibition of MyD88-TLR4 interaction and downstream NF-κB activation. Treatment with LM8 (5, 10 mg/kg, i.g.) significantly reduced renal inflammation and fibrosis and preserved renal function in both type 1 and type 2 diabetic mice. These renoprotective effects were associated with reduced MyD88-TLR4 complex formation, suppressed NF-κB signaling, and prevention of inflammatory factor expression. Collectively, our results show that hyperglycemia activates MyD88 signaling cascade to induce renal inflammation, fibrosis, and dysfunction. Pharmacological inhibition of MyD88 may be a therapeutic approach to mitigate diabetic nephropathy and the inhibitor LM8 could be a potential candidate for such therapy.